Article

AG-120, an Oral, Selective, First-in-Class, Potent Inhibitor of Mutant IDH1, Reduces Intracellular 2HG and Induces Cellular Differentiation in TF-1 R132H Cells and Primary Human IDH1 Mutant AML Patient Samples Treated Ex Vivo

2014-12-06

Abstract excerpt

Abstract Point mutations in isocitrate dehydrogenase (IDH) define distinct subsets of acute myelogenous leukemia (AML). IDH is a metabolic enzyme that interconverts isocitrate and α-ketoglutarate (α-KG), but cancer-associated point mutations in IDH1 and IDH2 confer a neomorphic activity that allows reduction of α-KG to the oncometabolite R-2-hydroxyglutarate (2-HG). High levels of 2-HG have been shown to inhibit α...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: f39e6bef-16a5-540f-b6dc-448a57e4f0c4
DOI: 10.1182/blood.v124.21.3734.3734

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

AG-120, an Oral, Selective, First-in-Class, Potent Inhibitor of Mutant IDH1, Reduces Intracellular 2HG and Induces Cellular Differentiation in TF-1 R132H Cells and Primary Human IDH1 Mutant AML Patient Samples Treated Ex VivoDOI 10.1182/blood.v124.21.3734.3734Read

Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant CancersSemantic proximity Read

AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations.Semantic proximity Read

Targeted Inhibition of Mutant IDH2 in Leukemia Cells Induces Cellular DifferentiationSemantic proximity Read

IDH mutations in cancer and progress toward development of targeted therapeutics.Semantic proximity Read

The role of mutant IDH1 and IDH2 inhibitors in the treatment of acute myeloid leukemia.Semantic proximity Read

Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo.Semantic proximity Read

Targeting IDH Mutations in AML: Wielding the Double-edged Sword of Differentiation.Semantic proximity Read

Recent advances of IDH1 mutant inhibitor in cancer therapySemantic proximity Read

New IDH1 mutant inhibitors for treatment of acute myeloid leukemia.Semantic proximity Read

Targeting IDH1 and IDH2 Mutations in Acute Myeloid Leukemia: Emerging Options and Pending QuestionsSemantic proximity Read

Isocitrate dehydrogenase (IDH) inhibition as treatment of myeloid malignancies: Progress and future directions.Semantic proximity Read

Inhibition of mutant IDH1 promotes cycling of acute myeloid leukemia stem cellsSemantic proximity Read